Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin

International Journal of Oncology

Volumn 43, Issue 5, 2013, Pages 1481-1486

  Chekhun, Vasyl F ^a   Lukyanova, Natalia Yu ^a   Burlaka, Anatoliy P ^a   Bezdenezhnykh, Natalia A ^a   Shpyleva, Svitlana I ^b   Tryndyak, Volodymyr P ^a,b   Beland, Frederick A ^b   Pogribny, Igor P ^b  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Breast cancer; Drug resistanceg; Iron metabolism

Indexed keywords

CISPLATIN; DOXORUBICIN; FERRITIN LIGHT CHAIN PROTEIN; IRON; IRON REGULATORY FACTOR; MICRORNA; MICRORNA 133A; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BREAST ADENOCARCINOMA; CANCER CELL; CANCER GROWTH; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IC 50; IRON METABOLISM; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOFERRITINS; BLOTTING, WESTERN; BREAST NEOPLASMS; CISPLATIN; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ELECTRON SPIN RESONANCE SPECTROSCOPY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IRON; MICRORNAS; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84885083036     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2063     Document Type: Article

References (34)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2011.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Gonzalez-Angulo AM, Morales-Vasquez F and Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22, 2007.
4. Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV and Torti FM: Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2: 43ra56, 2010.
5. Torti SV and Torti FM: Ironing out cancer. Cancer Res 71: 1511-1514, 2011.
6. Miller LD, Cofman LG, Chou JW, Black MA, Bergh J, D'Agostino R Jr, Torti SV and Torti FM: An iron gene signature predicts outcome in breast cancer. Cancer Res 71: 6728-6737, 2011.
7. Kwok JC and Richardson DR: The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Oncol Hematol 42: 65-78, 2002.
8. Yu Y, Gutierrez E, Kovacevic Z, Saletta F, Obeidy P, Rahmanto YS and Richardson DR: Iron chelators for the treatment of cancer. Curr Med Chem 19: 2689-2702, 2012.
9. Hoke EM, Maylock CA and Shacter E: Desferal inhibits tumor growth and does not interfere with tumoricidal activity of doxorubicin. Free Radic Biol Med 39: 403-411, 2005.
10. Rao VA, Klein SR, Agama KK, Toyoda E, Adaci N, Pommier Y and Shacter EB: The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase II alpha in breast cancer cells. Cancer Res 69: 948-957, 2009.
11. Whitnall M, Howard J, Ponka P and Richardson DR: A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 103: 14901-14906, 2006.
12. Chekhun VF, Lukyanova NYu, Kovalchuk O, Tryndyak VP and Pogribny IP: Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. Mol Cancer Ther 6: 1089-1098, 2007.
13. Kars MD, Iseri OD, Gündüz U, Ural AU, Arpaci F and Molnár J: Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res 26: 4559-4568, 2006.
14. Pate KT, Randel NA, Fraser B, Clement MH and Srinivasan C: Measuring 'free' iron levels in Caenorhabditis elegans using low-temperature Fe(III) electron paramagnetic resonance spectroscopy. Anal Biochem 358: 199-207, 2006.
15. McClelland RA, Wilson D and Leake R: A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification. Eur J Cancer 27: 711-715, 1991.
16. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
17. Ni J and Hollander D: Application of the MTT-assay to functional studies of mouse intestinal intraepithelial lymphocytes. J Clin Lab Anal 10: 42-52, 1996.
18. Shpyleva SI, Tryndyak VP, Kovalchuk O, Starlard-Davenport A, Chekhun VF, Beland FA and Pogribny IP: Role of ferritin alterations in human breast cancer cells. Breast Cancer Res Treat 126: 63-71, 2011.
19. Arosio P, Ingrassia and Cavadini P: Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta 1790: 589-599, 2009.
20. Dorr RT: Bleomycin pharmacology: mechanism of action and resistance and clinical pharmacokinetics. Semin Oncol 19 (Suppl 5): 3-8, 1992.
21. Wu Z, Wang C, Xiang R, Liu X, Ye S, Yang X, Zhang G, Xu X, Zhu T and Wu Q: Loss of miR133a expression is associated with poor survival of breast cancer and restoration of miR-133a expression inhibited breast cancer growth and invasion. BMC Cancer 12: 51, 2012.
22. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF and Pogribny IP: Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7: 2152-2159, 2008.
23. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI and Kovalchuk O: Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 127: 1785-1794, 2010.
24. Kanojia D, Zhou W, Zhang J, Jie C, Lo PK, Wang Q and Chen H: Proteomic profiling of cancer stem cells from primary tumors of HER2/Neu transgenic mice. Proteomics 12: 3407-3415, 2012.
25. Eswaran J, Cyanam D, Mudravi P, Reddy SD, Pakala SB, Nair SS, Florea L, Fuqua SA, Godbole S and Kumar R: Transcriptomic landscape of breast cancers through mRNA sequencing. Sci Rep 2: 264, 2012.
26. Descotes F, Jézéquel P, Spyratos F, Campion L, Grenot C, Lerebours F, Campone M, Guérin-Charbonnel C, Lanoë D, Adams Mandré J, Carlioz A, Martin PM, Chassevent A, Jourdan ML, Guette C, Zanella-Cleon I and Ricolleau G: Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: a multicentric 2004 national PHRC study. Int J Oncol 41: 92-104, 2012.
27. Dong X, Yang M, Sun H, Lü J, Zheng Z, Li Z and Zhong L: Combined measurement of CA 15-3 with novel autoantibodies improves diagnostic accuracy for breast cancer. Onco Targets Ther 6: 273-279, 2013.
28. Xu X, Persson HL and Richardson DR: Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol 68: 261-271, 2005.
29. Xu X, Sutak R and Richardson DR: Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking. Mol Pharmacol 73: 833-844, 2008.
30. Canzoneri JC and Oyelere AK: Interaction of anthracyclines with iron responsive elements mRNAs. Nucleic Acids Res 36: 6825-6834, 2008.
31. Thompson KJ, Fried MG, Ye Z, Boyer P and Connor JR: Regulation, mechanisms and proposed function of ferritin translocation to cell nuclei. J Cell Sci 114: 2165-2177, 2002.
32. Alkhateeb AA and Connor JR: Nuclear ferritin: a new role for ferritin in cell biology. Biochim Biophys Acta 1800: 793-797, 2010.
33. Yang DC, Jiang X, Elliot RL and Head JF: Antisense ferritin oligonucleotides inhibit growth and induce apoptosis in human breast carcinoma cells. Anticancer Res 22: 1513-1524, 2002.
34. Liu X, Madhankumar AB, Slagle-Webb B, Sheehan JM, Surguladze N and Connor JR: Heavy chain ferritin siRNA delivered by cationic liposomes increases sensitivity of cancer cells to chemotherapeutic agents. Cancer Res 71: 2240-2249, 2011.